Apogee Therapeutics, Inc. (APGE) - Q3 2024 10-Q Summary
Business Context and Reporting Period
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company developing novel biologics for inflammatory and immunology (I&I) indications, including atopic dermatitis, asthma, and COPD. The company operates as a non-accelerated filer and emerging growth company. This report covers the quarterly period ended September 30, 2024.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(49.0) million | $(20.8) million | $(114.9) million | $(52.3) million |
| Operating Expenses | $58.7 million | $24.3 million | $141.0 million | $55.8 million |
| Research & Development (R&D) | $45.7 million | $17.1 million | $107.6 million | $39.5 million |
| General & Administrative (G&A) | $13.0 million | $7.2 million | $33.4 million | $16.4 million |
| Interest Income, Net | $9.7 million | $3.5 million | $26.1 million | $3.6 million |
| Cash & Cash Equivalents | $118.8 million (as of Sept 30, 2024) | |||
| Marketable Securities (Current) | $407.3 million (as of Sept 30, 2024) | |||
| Marketable Securities (Long-term) | $227.7 million (as of Sept 30, 2024) | |||
| Total Liquidity | $753.8 million (as of Sept 30, 2024) | |||
| Accumulated Deficit | $(238.7) million (as of Sept 30, 2024) |
Material Changes vs. Prior Period
- Expense Growth: Total operating expenses increased by $34.4 million (141%) for the three months ended September 30, 2024, compared to the same period in 2023. R&D expenses rose $28.6 million, driven by the advancement of APG777, APG808, APG990, and APG333 into clinical trials and increased personnel costs.
- Net Loss Expansion: Net loss for the quarter increased to $49.0 million from $20.8 million year-over-year, primarily due to higher operating expenses, partially offset by a $6.2 million increase in interest income.
- Capital Raise: In March 2024, the company completed a public offering raising approximately $450.0 million in net proceeds, significantly bolstering its cash position compared to the prior year.
- Investing Activity: Net cash used in investing activities was $346.8 million for the nine months ended September 30, 2024, primarily due to the purchase of marketable securities ($588.9 million) offset by maturities ($243.2 million).
Guidance, Outlook, and Risks
- Liquidity Outlook: Management estimates that existing cash, cash equivalents, and marketable securities ($753.8 million) are sufficient to fund operating expenses and capital requirements into the first quarter of 2028.
- Development Milestones:
- APG777 (anti-IL13): Phase 2 trial in atopic dermatitis commenced in May 2024; topline data expected in H2 2025.
- APG808 (anti-IL4Rα): Phase 1 dosing in asthma patients commenced in September 2024; interim data expected in Q4 2024.
- APG990 (anti-OX40L): Phase 1 dosing commenced in August 2024.
- APG333 (anti-TSLP): Development candidate nominated in October 2024; Phase 1 expected to initiate in late 2024 or early 2025.
- Subsequent Events: In October 2024, the company finalized the nomination of a development candidate for APG333 and expects to pay a $3.0 million milestone to Paragon Therapeutics in Q4 2024.
- Risks: The company has no approved products and has not generated revenue. Future success depends on clinical trial outcomes, regulatory approvals, and the ability to raise additional capital if needed. The company relies heavily on third-party manufacturers (e.g., WuXi Biologics) and collaborators (e.g., Paragon).
Investor Verification Checklist
- Verify the timeline and enrollment progress of the APG777 Phase 2 trial, as this is the most advanced program.
- Monitor the upcoming Q4 2024 interim Phase 1 data for APG808 and the safety profile of the extended half-life technology.
- Confirm the impact of the $3.0 million milestone payment to Paragon on Q4 2024 cash flow and R&D expenses.
- Review the company's burn rate relative to the $753.8 million liquidity position to validate the 2028 runway estimate.
- Assess the status of the $300 million ATM facility established in August 2024 (no sales made as of Sept 30, 2024).